With the ambition to become a world-leading clinical oligonucleotide research company, Ribocure Pharmaceuticals AB has established Ribocure Clinic, to focus on high-quality Proof of Principle Ph2 studies. The clinic has now dosed its first patient in a Phase 2 study using the world’s first and most advanced hemostasis sparing anti-thrombotic siRNA drug, RBD4059.
Ribocure Clinic, the Clinical Trial Unit (CTU) of Ribocure Pharmaceuticals AB and Suzhou Ribo Life Science Ltd., is located at GoCo Health Innovation City in Mölndal, Sweden. This Phase 2 trial unit invites study participants to take part in clinical trials conducted by experienced and highly trained medical research staff. The CTU specializes in advanced Phase 2 trial endpoints in cardiovascular, pulmonary, renal, and liver areas, requiring advanced imaging and functional assessments.
“The first patient dosed in our newly established CTU marks a significant milestone for our future endeavors in RNA-based therapeutics. Ensuring high-quality execution of Proof of Principle/concept studies is of ultimate importance in the drug development process. The setup established at Ribocure clinic consists of multiple aspects representing several of the most innovative concepts within clinical trial excellence, including precision medicine approach using deep phenotyping concept ensuring right patients for the right interventional trials, multi-dimensional physiological and molecular trial endpoints etc. Really looking forward to witnessing significant acceleration of our R&D capacity with this novel clinical capacity now up and running,” says Li-Ming Gan, MD, PhD, and CEO of Ribocure Pharmaceuticals and co-CEO of Suzhou Ribo Life Science.
“As medical doctors, this is extremely rewarding and indeed a dream come true. We have successfully transitioned from target idea to patient treatment in a short timeframe, addressing high unmet medical needs. And this is just the beginning!” continues Sara Svedlund, MD, PhD, and Head of Ribocure Clinic.
About RBD4059
The first Phase 2 study utilizes FXI-targeting siRNA RBD4059, based on the RIBO-GalSTARTM liver targeting technology platform. This randomized, double-blind, placebo-controlled trial aims to evaluate the safety, pharmacokinetics, and pharmacodynamics of RBD4059 in participants with stable coronary artery disease. The study seeks to demonstrate proof of principle and confirm dose response in the target population.
